Lupin announces closure of US FDA insepction of Nagpur facility with zero observations
Lupin has announced that the United States Food and Drug Administration’s inspection of its Nagpur facility has come to a close. In an exchange filing published on November 15, the pharma company said that the drug regulator concluded the inspection

